West Pharmaceutical Services INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Vanguard Capital Management has reported a beneficial ownership of 7.48% in West Pharmaceutical Services Inc. common stock as of March 31, 2026.
NYSE
Vanguard Portfolio Management has reported beneficial ownership of 5.69% of West Pharmaceutical Services Inc. common stock as of March 31, 2026.
NYSE
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in West Pharmaceutical Services Inc. following an internal realignment.
NYSE
The Vanguard Group reports a 13.49% beneficial ownership in West Pharmaceutical Services Inc. as of September 30, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.4% Stake in West Pharmaceutical Services Inc. via Amended Schedule 13G Filing
BlackRock, Inc. has filed an amended Schedule 13G, reporting an 8.4% beneficial ownership stake in West Pharmaceutical Services Inc. as of March 31, 2025.